Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 studies of ziftomenib plus standard induction or nonintensive therapy in newly diagnosed NPM1-mutated or KMT2A-rearranged AML
2025-521314-25-00Phase 3Authorised
- Sponsor
- Kura Oncology
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of ziftomenib in acute myeloid leukemia (AML) (4 arms), sponsored by Kura Oncology. Primary endpoints: Overall survival and Event-free survival. Planned start Mar 2026; status: authorised.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-521314-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521314-25-00.